Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies

Brentuximab vedotin, a CD30‐directed antibody‐drug conjugate (ADC), is approved for treating certain patients with CD30‐expressing hematologic malignancies. Its primary mechanism of action is the targeted delivery of a microtubule‐disrupting agent, monomethyl auristatin E (MMAE), to CD30‐expressing...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong, Han, Tae H., Hunder, Naomi N., Jang, Graham, Zhao, Baiteng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574006/
https://www.ncbi.nlm.nih.gov/pubmed/28513851
http://dx.doi.org/10.1002/jcph.920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574006/
https://www.ncbi.nlm.nih.gov/pubmed/28513851
http://dx.doi.org/10.1002/jcph.920

Ejemplares similares